Andrew Mignatti

Andrew is an accomplished molecular diagnostics industry professional, having spent over 20 years in the field. Andrew began his career at Allergy Testing Laboratory and became the regional director of sales before the company was ultimately acquired by LabCorp. As the director of business development at LabCorp, Andrew gained valuable insight into the operations of a major laboratory as he led the company through multiple successful acquisitions in his division.

Prior to CMT Solutions, Andrew held executive leadership roles for molecular diagnostics companies, RedPath Integrated Pathology (now Interpace Diagnostic), and then was the CEO for Perthera. At Perthera, Andrew successfully raised $10million in capital funding and doubled the company’s revenue during his tenure, taking it from a small start-up to a fully operating business.

CMT Solutions was founded in 2017, and Andrew has delivered extraordinary results in a short period of time. He has built a fully functioning proprietary automated software system, partnered with over 20 laboratories, including Quest and LabCorp, and grown a successful business from the ground up. His vision is to help all patients gain access to the correct personal medical diagnostic test for them to best manage their condition or disease.